The Raji line of human lymphoblastoid cells, which does not show expression of Epstein-Barr virus, was made resistant to 5-bromodeoxyuridine. Within several weeks after removal of the drug, Epstein-Barr virus particles were detected in the cells. The 
The human herpesvirus, Epstein-Barr virus (EB virus), has been implicated as the agent responsible for lymphocyte transformation in vitro (1, 2) . While some lymphoblastoid cell lines show persistent infection with EB virus, other longterm cell lines have remained virus-negative. Recent findings (3, 4) suggest the presence in some "virus-negative" cell lines of at least a portion of the EB virus genome.
A report from this laboratory (5) described the properties of an EB virus-positive cell line (P3HR-1) made resistant to BrdU. The results indicated persistence of a repressed EB virus genome in virus-negative cells, with spontaneous virus activation being accompanied by productive infection and activation of thymidine kinase enzyme (EC 2.7.1.21).
The present studies describe the properties of an EB virusnegative cell line (Raji) made resistant to BrdU. Evidence is presented of BrdU activation of a repressed EB virus genome in drug-resistant Raji cells, with synthesis of EB virus particles. In separate and independent studies (6), Gerber has also obtained evidence of BrdU activation of the Epstein-Barr virus genome in "virus-negative" cells. The independent findings of these two laboratories demonstrate the efficacy of BrdU for activating a repressed EB virus genome. Recent findings from Rowe's laboratory (7) and others (8) Immunofluorescence, Electron Microscopy, and Autoradiography. The procedures were described (5) . The cells were first tested by indirect immunofluorescence and were then tested for isotope incorporation by autoradiography.
Rabbit antisera specific for EB capsids and human anti-EB virus sera were conjugated with ferritin for use in the immunoferritin test (10) .
Incorporation of Isotopes into Cell DNA. Cells labeled with appropriate isotopes were lysed and precipitated with Cl3r
CCOOH as described (5 taining hypoxanthine-aminopterin-thymidiine (5 No observations for EB virus replication by immunofluorescence or electron microscopy were performed until the Raji-(BrdU) cells and P3HR-1 (BrdU) cells had developed resistance to 30 ,/g/ml of BrdU. As reported for P3HR-1 (BrdU) cells (5), the properties of Raji(BrdU) cells remained essentially constant at BrdU concentrations of 30,g/inl and higher.
Raji(BrdUT) cells were tested frequently by immunofluorescence, in parallel with P3HR-1 (BrdU) cells, by use of the same concentration of reagents that were optimal for detecting viral antigens in productively infected cells (5) . When tested by immunofluorescence after 7 days growth at 370C in the presence of BrdU or after an additional 7 days incubation at 330C, the Raji(BrdU) cells occasionally showed verylow-intensity fluorescent staining not seen in control Raji cells. Raji(BrdU) cells showed no evidence of EB virus by electron microscopy. This contrasted with P3HR-1 (BrdU) cells maintained on BrdU; fluorescent staining was correlated with findings by electron microscopy of nuclear changes characteristic of herpesvirus infection ("fingerprints") (5) .
When P3HR-1 (BrdU) cells were washed free of BrdU and passaged in medium alone, the intensity of the fluorescentantibody staining was enhanced, and virus particles appeared within 4 days (5). In the case of Raji(BrdU) cells maintained on drug-free medium, bright fluorescent-antibody staining and EB virus particles were not detected for several weeks ( Table   1 ).
The first drug-free Raji(BrdU) cell line [Raji(BrdU49) ] was initiated with cells that had been maintained 49 days in the presence of 100 1g/ml of BrdU.
The Raji(BrdU49) cells showed bright fluorescent staining on day 28 and virus particles on day 63 after removal of the BrdU (Table 1 t Cells were removed from drug after 49 days in the presence of 100,g of BrdU per ml of medium. I Cells were removed from drug after 77 days in the presence of 100 /(g of BrdU per ml of medium. § Number of days during which the cells were maintained in drug-free medium. Cells were passaged at 7-day intervals. ¶ Cells were tested after 7-days growth at 370C in drug-free medium.
I I Cells were tested at this time and at subsequent times after 7-days growth at 370C, followed by an additional 7-days incubation at 330C in drug-free medium.
particles, and about 2-3% of the remaining cells showed herpesvirus "fingerprints". The herpesvirus "fingerprints" observed in drug-free Raji(BrdU) cells were limited essentially to chromatin margination (Fig. 1A) , and nuclear membrane reduplication was limited to cells showing virus particles. This differed from P3HR-1 (BrdU) cells maintained on BrdU (5), whose "fingerprints" were characterized by extensive chromatin margination and nuclear membrane reduplication, although virus particles were absent. Since the effect of BrdU in P3HR-1 (BrdU) cells was to inhibit virus assembly, it would appear that nuclear membrane reduplication is limited to cells that produce EB virus.
The EB virus particles in drug-free Raji(BrdU) cells showed ferritin tagging with both human and rabbit antisera to EB virus (Fig. 1B) . The majority of the particles observed in Raji(BrdU) cells were capsids (full and empty), with only an occasional particle showing evidence of envelope formation. Virus capsids also predominated in P3HR-1 (BrdU) cells (5 (14, 15) . Two similar radioactive peaks that banded at densities of about 1.69 g/cm3 and 1.71 g/cm3 were observed with P3HR-1 (BrdU) cell DNA (5) .
Relationship between EB virus production and thvinidine kinase activity in Raji(BrdU) cells When P3HR-1 (BrdU) cells labeled with [3H ]dT were tested by immunofluorescence and autoradiography, thymidine kinase activity (as measured by incorporation of the isotope) was limited to cells producing viral antigen (5) . Similar studies were performed with drug-free Raji(BrdU) cells (Table 2) .
When tested on day 16 in drug-free medium (before the appearance of EB virus), about 1% of the Raji(BrdU49) cells showed thymidine kinase activity that was not correlated with viral antigen synthesis (detected by immunofluorescence). When tested on day 65, all of the fluorescent antibody-positive cells were also positive for thymidine kinase, although some enzyme-positive cells were still negative for viral antigen. By day 77, however, all of the cells positive for thymidine kinase were also positive for viral antigen.
DISCUSSION
Two significant conclusions may be drawn from these findings. First, the human EB virus genome maintained in Raji cells in a repressed state may be activated after treatment with BrdU. Second, at least some Raji cells must contain an essentially complete EB virus genome, since virus particles were detected after activation. This second finding agrees with and adds to observations with Raji cells reported by other investigators (3, 4) who used nucleic acid hybridization techniques.
Before the appearance of virus, the properties of the Raji-(BrdU) cells differed significantly from those of virus-producing P3HR-1 (BrdU) cells (5 The first indication of EB virus activation in Raji(BrdU) cells was the expression of thymidine kinase in the absence of virus synthesis. Virus synthesis in these cells was not seen until they had been maintained for several weeks in drug-free medium. This suggested a step for virus synthesis in Raji(BrdU) cells that was not required in P3HR-1 (BrdU) cells. This added step apparently required replication of virus-negative Raji-(BrdU) cells expressing thymidine kinase. As expected, the activation of this added step was inhibited when thymidine kinase-positive cells were maintained continuously in medium with BrdU, due probably to the lethal effects of the incorporated drug.
Differences were also apparent in the ability of Raji(BrdU) cells and P3HR-1 (BrdU) cells to synthesize complete virus particles. In the case of P3HR-1 (BrdU) cells, removal of the drug was accompanied by synthesis of virus particles in essentially all fluorescent antibody-positive cells. Even when P3HR-l (BrdU) cells were maintained continuously on the drug, definite herpesvirus "fingerprints" characterized by chromatin margination and nuclear membrane reduplication were evident, although virus assembly was inhibited (5). In the case of Raji(BrdU) cells, drug removal was followed eventually by the appearance of fluorescent antibody-positive cells and herpesvirus "fingerprints". However, the percentage of fluorescent antibody-positive cells was appreciably higher than the percentage of cells showing "fingerprints". Further, the "fingerprints" in Raji(BrdU) cells were limited essentially to chromatin margination, with nuclear membrane reduplication being limited to the few cells producing virus. In most of the Raji(BrdU) cells, virus synthesis was incomplete. This indicated wide variations in the competency of Raji(BrdU) cells to sustain productive virus infection.
The above discussion is necessarily limited to Raji(BrdU) cells studied under the conditions and during the time period described. We have no information, for example, concerning 1 (BrdU) cells within 4 days after removal of the drug, and after the possible activation of EB virus in BrdU-susceptible cells
